A5011891928- Parathyroid Disorders and Treatments
- Magnesium in Health and Disease
- Vitamin D Research Studies
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Myofascial pain diagnosis and treatment
- Chronic Kidney Disease and Diabetes
- Renal Diseases and Glomerulopathies
- Pharmacological Effects and Toxicity Studies
- Metabolism, Diabetes, and Cancer
- Diabetes Treatment and Management
- Pain Mechanisms and Treatments
- Pancreatitis Pathology and Treatment
- Musculoskeletal pain and rehabilitation
Nagoya University
2011-2022
Ogaki Municipal Hospital
2020
IntroductionThe clinical trial on the Development of a treatment strategy for chronic kidney disease‒mineral and bone disorder by mUltilateral mechanism ETelcalcetide hydrochloride, or DUET trial, was designed to determine efficacy etelcalcetide, an intravenous calcimimetic, control secondary hyperparathyroidism (SHPT).MethodsEligible SHPT maintenance hemodialysis patients (n = 124) were randomized (1:1:1) inclusion in 12-week, multicenter, open-label, parallel-group study (jRCTs041180108),...
Recently, we demonstrated the efficacy of etelcalcetide in control secondary hyperparathyroidism (SHPT). This post hoc analysis aimed to evaluate changes fibroblast growth factor-23 (FGF23) and calciprotein particles (CPPs) after treatment with calcimimetics.The DUET trial was a 12-week multicenter, open-label, parallel-group, randomized (1:1:1) study patients treated plus active vitamin D (E + group; n = 41), oral calcium Ca or (C 42) under maintenance haemodialysis. Serum levels FGF23 CPPs...
Abstract Aims/Introduction The relationship between renal function and urinary glucose is poorly understood in diabetes patients who are not using sodium–glucose cotransporter 2 inhibitors. This study aimed to investigate the association of excretion with prognosis such patients. Materials Methods retrospective cohort included 1,172 type 1 or mellitus. Patients were recruited data collected January 2007 31 December 2011; follow‐up until 30 June 2015. primary outcome was set as a 30% decline...
Secondary hyperparathyroidism (SHPT) is a common complication in advanced chronic kidney disease (CKD). The aims of this study are to clarify the efficacy etelcalcetide, novel-approved intravenous calcimimetic, for evaluating optimal therapy etelcalcetide-induced hypocalcemia, and identify sensitive markers vascular calcification patients undergoing maintenance dialysis. Development treatment strategy CKD-MBD by mUltilateral mechanism ETelcalcetide hydrochloride (DUET) 12-week multicenter,...